{"id":33171,"date":"2025-05-12T14:53:56","date_gmt":"2025-05-12T06:53:56","guid":{"rendered":"https:\/\/flcube.com\/?p=33171"},"modified":"2025-05-12T14:53:57","modified_gmt":"2025-05-12T06:53:57","slug":"shanghai-escugen-partners-with-conjugatebio-on-ezwi-fit-platform-for-adc-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33171","title":{"rendered":"Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development"},"content":{"rendered":"\n<p>China-based Shanghai Escugen has entered into an exclusive option agreement with US-headquartered ConjugateBio Inc. regarding its EZWi-Fit platform. This next-generation linker payload technology platform offers significant competitive advantages in safety, efficacy, drug resistance, and pharmacokinetic characteristics.<\/p>\n\n\n\n<p><strong>Agreement Details<\/strong><br>Under the terms of the agreement, ConjugateBio, upon payment of an option fee to Escugen, secures the exclusive right to utilize Escugen\u2019s EZWi-Fit platform technology for the development of antibody drug conjugate (ADC) products targeting specified therapeutic areas. Upon exercising the option, ConjugateBio will acquire a global exclusive license for these products.<\/p>\n\n\n\n<p><strong>Financial Terms<\/strong><br>Escugen stands to receive over USD 100 million in payments tied to development, regulatory, and commercialization milestones. Additionally, the company is entitled to tiered royalties based on the global annual net sales of the licensed products.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Shanghai Escugen has entered into an exclusive option agreement with US-headquartered ConjugateBio Inc. regarding&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33173,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[35,4059,464],"class_list":["post-33171","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-adc-xdc","tag-conjugatebio","tag-escugen"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Shanghai Escugen has entered into an exclusive option agreement with US-headquartered ConjugateBio Inc. regarding its EZWi-Fit platform. This next-generation linker payload technology platform offers significant competitive advantages in safety, efficacy, drug resistance, and pharmacokinetic characteristics.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33171\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development\" \/>\n<meta property=\"og:description\" content=\"China-based Shanghai Escugen has entered into an exclusive option agreement with US-headquartered ConjugateBio Inc. regarding its EZWi-Fit platform. This next-generation linker payload technology platform offers significant competitive advantages in safety, efficacy, drug resistance, and pharmacokinetic characteristics.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33171\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-12T06:53:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T06:53:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1210.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33171#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33171\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development\",\"datePublished\":\"2025-05-12T06:53:56+00:00\",\"dateModified\":\"2025-05-12T06:53:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33171\"},\"wordCount\":143,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33171#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1210.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"ConjugateBio\",\"Escugen\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33171#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33171\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33171\",\"name\":\"Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33171#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33171#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1210.webp\",\"datePublished\":\"2025-05-12T06:53:56+00:00\",\"dateModified\":\"2025-05-12T06:53:57+00:00\",\"description\":\"China-based Shanghai Escugen has entered into an exclusive option agreement with US-headquartered ConjugateBio Inc. regarding its EZWi-Fit platform. This next-generation linker payload technology platform offers significant competitive advantages in safety, efficacy, drug resistance, and pharmacokinetic characteristics.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33171#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33171\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33171#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1210.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1210.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33171#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Shanghai Escugen has entered into an exclusive option agreement with US-headquartered ConjugateBio Inc. regarding its EZWi-Fit platform. This next-generation linker payload technology platform offers significant competitive advantages in safety, efficacy, drug resistance, and pharmacokinetic characteristics.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33171","og_locale":"en_US","og_type":"article","og_title":"Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development","og_description":"China-based Shanghai Escugen has entered into an exclusive option agreement with US-headquartered ConjugateBio Inc. regarding its EZWi-Fit platform. This next-generation linker payload technology platform offers significant competitive advantages in safety, efficacy, drug resistance, and pharmacokinetic characteristics.","og_url":"https:\/\/flcube.com\/?p=33171","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-12T06:53:56+00:00","article_modified_time":"2025-05-12T06:53:57+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1210.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33171#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33171"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development","datePublished":"2025-05-12T06:53:56+00:00","dateModified":"2025-05-12T06:53:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33171"},"wordCount":143,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33171#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1210.webp","keywords":["ADC \/ XDC","ConjugateBio","Escugen"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33171#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33171","url":"https:\/\/flcube.com\/?p=33171","name":"Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33171#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33171#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1210.webp","datePublished":"2025-05-12T06:53:56+00:00","dateModified":"2025-05-12T06:53:57+00:00","description":"China-based Shanghai Escugen has entered into an exclusive option agreement with US-headquartered ConjugateBio Inc. regarding its EZWi-Fit platform. This next-generation linker payload technology platform offers significant competitive advantages in safety, efficacy, drug resistance, and pharmacokinetic characteristics.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33171#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33171"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33171#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1210.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1210.webp","width":1080,"height":608,"caption":"Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33171#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1210.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33171"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33171\/revisions"}],"predecessor-version":[{"id":33174,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33171\/revisions\/33174"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33173"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}